Lonza, Emerald Health Pharmaceuticals To Produce Cannabinoid-Derived Drug Candidate
14th February 2019
San Diego, US-based Emerald Health Pharmaceuticals (EHP) and Swiss Lonza have announced an agreement for the large-scale manufacturing of a new synthetic derivative of cannabidiol and its oral drug product for the treatment of multiple sclerosis (MS) and systemic scleroderma, also known as systemic sclerosis. Under the terms of the agreement, Lonza will synthesize the active pharmaceutical ingredient (API) and develop the drug product as liquid-filled capsules.
“As Emerald Health Pharmaceuticals advances through clinical trials, we will be supporting them with an integrated API and specialized liquid encapsulation solution,” said Christian Dowdeswell, head of dosage forms & delivery systems at Lonza. “Patients will benefit from cGMP-quality therapies in an accessible and efficient format.”
According to the partnering companies the purpose of this agreement is to enable the development and future commercialization of a novel cannabinoid-based medicine for therapeutic applications across a broad range of diseases. “We firmly believe that novel cannabinoid-derived molecules with a unique combination of pharmacological properties have the potential to be developed into safe and effective prescription drugs that can be of great benefit in treating patients with life-threatening diseases that currently have no cure,” said Jim DeMesa, CEO of Emerald Health Pharmaceuticals. “This agreement with Lonza will help us meet this vision.”
For more information visit www.chemanager-online.com/en/